Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

4.50
+0.02000.45%
Post-market: 4.500.00000.00%19:30 EDT
Volume:3.51M
Turnover:15.73M
Market Cap:387.95M
PE:-1.20
High:4.59
Open:4.44
Low:4.37
Close:4.48
52wk High:19.11
52wk Low:3.95
Shares:86.21M
Float Shares:60.67M
Volume Ratio:0.80
T/O Rate:5.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:2.33
PE(LYR):-1.42

Loading ...

Top Executive Makes Strategic Move With EyePoint Pharmaceuticals Stock

TIPRANKS
·
Apr 21

EyePoint Chief Medical Officer Ramiro Ribeiro disposes of 2,437 shares for $36,555

Reuters
·
Apr 21

BRIEF-Eyepoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 17

EyePoint grants inducement stock options for 362,500 shares to 14 new employees

Reuters
·
Apr 17

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 17

Assessing EyePoint (EYPT) Valuation After DURAVYU Phase 3 And Manufacturing Expansion Update

Simply Wall St.
·
Apr 15

EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway

TIPRANKS
·
Apr 14

U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan

Reuters
·
Mar 30

EyePoint Files Complaint Against Ocular Alleging False or Misleading Claims Regarding Duravyu

MT Newswires Live
·
Mar 23

BRIEF-Eyepoint Files Complaint Against Ocular Therapeutix In Middlesex County Superior Court

Reuters
·
Mar 21

EyePoint Sues Ocular Therapeutix Over Alleged Defamation

TIPRANKS
·
Mar 21

EyePoint Inc - Files Complaint Against Ocular Therapeutix in Middlesex County Superior Court for Commonwealth of Massachusetts on March 20, 2026

THOMSON REUTERS
·
Mar 21

EyePoint Inc - Complaint Alleges Ocular Therapeutix Disseminated False Statements About EyePoint and Duravyu - SEC Filing

THOMSON REUTERS
·
Mar 21

EyePoint Inc - Complaint Asserts Defamation, Commercial Disparagement, and Tortious Interference Claims - SEC Filing

THOMSON REUTERS
·
Mar 21

EyePoint sues Ocular Therapeutix over alleged false statements about DURAVYU clinical results

Reuters
·
Mar 21

A Look At EyePoint Pharmaceuticals (EYPT) Valuation Following Recent Mixed Share Price Performance

Simply Wall St.
·
Mar 19

EyePoint (EYPT) Is Down 14.2% After Weak Q4 Results And DURAVYU Optimism - What's Changed

Simply Wall St.
·
Mar 18

EyePoint President and CEO Jay S. Duker acquires USD 19,724 of common shares

Reuters
·
Mar 17

EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus

TIPRANKS
·
Mar 17

EyePoint reports inducement grants under NASDAQ listing rule

TIPRANKS
·
Mar 16